within the rapidly evolving discipline of oncology research, precise and successful mutation screening is critical for producing focused therapies. The KRAS companies Platform plays a pivotal role in this landscape by featuring in depth answers for KRAS mutation profiling and Assessment. KRAS mutations, found in about ninety five% of RAS-similar on